m
Recent Posts
Connect with:
Wednesday / July 17.
HomeminewsHoya Reveals Latest Myopia Management Findings

Hoya Reveals Latest Myopia Management Findings

Hoya Vision Care has shared the latest findings of the clinical application of the MiYOSMART spectacle lens, and its role in myopia management, at the International Myopia Conference (IMC), held 4-7 September 2022 in Rotterdam, The Netherlands.

During a myopia symposium, hosted by Hoya, renowned key opinion leaders shared new European data and discussed topics including emmetropic eye growth, combination treatment and relative peripheral refraction (RPR).

We are very pleased to be able to share the latest evidence-based approach to myopia management at IMC 2022

Dr Andrea Lembo, from the University Hospital San Giuseppe Multimedica in Milan, Italy, shared the results of a clinical application of the MiYOSMART spectacle lens in combination with 0.01% Atropine drops in European myopic children and adolescents, demonstrating that over one-year, axial elongation and myopia progression were reduced with maximum effect using the combination treatment.1

Further to this, Professor Hakan Kaymak, from the Internationale Innovative Ophthalmochirurgie in Duesseldorf, Germany, presented the findings of his study on axial length growth under treatment with MiYOSMART spectacle lenses. The data of German children wearing MiYOSMART spectacle lenses reconfirmed previous clinical study results, with further findings showing that children adapt very well to MiYOSMART spectacle lenses with no safety concerns even in combination with low-dose atropine.1

In addition, Professor Carly Lam, from The Hong Kong Polytechnic University, shared how myopia control effect may be influenced by baseline relative peripheral refraction in children wearing the MiYOSMART spectacle lens with D.I.M.S. Technology.1 The results showed that myopia control effect was stronger in children with baseline hyperopic RPR than in children with baseline myopic RPR.1

“We are very pleased to be able to share the latest evidence-based approach to myopia management at IMC 2022,” said May Zhang, Global Head of Professional Affairs. “Hoya Vision Care continues to be a leader in addressing myopia in children and championing new practices, like the successful combination treatment of the MiYOSMART spectacle lens and Atropine drops, as well as continued support of clinical studies in multiple countries to help eye care professionals make informed decisions.”

MiYOSMART was launched in 2018 and is available in 28 markets, including Australia and New Zealand, with two million spectacle lenses purchased by parents around the world.2

References

  1. Kaymak H, Lembo A, Lam CSY. HOYA Vision Care Myopia Symposium ” New Insights to Advance Myopia Management”: Axial length growth under therapy with MiYOSMART spectacle lenses; A comparison of myopia control in European children with Defocus Incorporated Multiple Segments (DIMS) spectacles, atropine, and combined DIMS/atropine; Myopia control effect is influenced by baseline relative peripheral refraction in children wearing Defocus Incorporated Multiple Segments (DIMS) spectacle lenses. International Myopia Conference (IMC) 2022, September 4, Rotterdam, The Netherlands.
  2. Based on number of MiYOSMART lenses sold per Hoya sales data on file as of June 2022.